Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Cancer is a major cause of death worldwide. Gastrointestinal (GI) cancers are still an important cause of tumor-related deaths. Conventional therapeutic approaches like surgery, chemotherapy, and radiation therapy are indispensable but insufficient. Despite the advances in immunotherapy and other conventional treatment strategies, some might argue that we are still far from curing cancer. Cancer stem cells (CSCs) might be to blame. Because sequencing technologies are moving fast in this precision-medicine era, molecular testing of tumors, circulating tumor cells, and CSCs have important implications for treatment decisions. Biomarkers offer prognostic values and targeted therapy availabilities as molecular predictive factors. CSCs are considered biomarkers of tumorigenesis development, metastasis, and recurrence. In this review, we summarize the important issues over CSCs and the development of new drugs that target GI CSCs.

More information Original publication

DOI

10.1615/critrevoncog.2018029633

Type

Journal article

Publication Date

2019-01-01T00:00:00+00:00

Volume

24

Pages

55 - 59

Total pages

4

Addresses

H, e, a, l, t, h, , I, n, s, t, i, t, u, t, e, , o, f, , T, u, r, k, e, y, ,, , T, u, r, k, i, s, h, , C, a, n, c, e, r, , I, n, s, t, i, t, u, t, e, ,, , 0, 6, 4, 3, 4, ,, , A, n, k, a, r, a, ,, , T, u, r, k, e, y, .

Keywords

Humans, Gastrointestinal Neoplasms, Disease Susceptibility, Antineoplastic Agents, Drug Resistance, Neoplasm, Neoplastic Stem Cells, Molecular Targeted Therapy, Biomarkers, Tumor